Navigation Links
Common virus may help doctors treat deadly brain tumors
Date:10/22/2007

DURHAM, N.C. -- A common human virus may prove useful in attacking the deadliest form of brain tumors, according to a study by researchers at Dukes Preston Robert Tisch Brain Tumor Center. The researchers said the finding is an important step in developing a vaccine that can attack the tumors by enlisting the help of the bodys immune system.

Human cytomegalovirus (HCMV), which infects 50 percent to 90 percent of people at some point during their lives, is active in more than 90 percent of patients diagnosed with glioblastoma multiforme, the most deadly type of malignant brain tumor, said Duane Mitchell, M.D., Ph.D., a brain cancer researcher and lead investigator on the study.

We dont know if the virus plays a part in the growth of the brain tumors or whether the presence of the brain tumors leads to a reactivation of the virus, Mitchell said. But we do know that the virus has the potential to affect the growth and invasiveness of cancer cells. So if we can target it, we may be able to empower the bodys immune system to fight infected tumor cells and destroy the cancer.

According to the researchers, a vaccine targeting HCMV likely would be administered to patients following conventional chemotherapy. The immune systems recovery from chemotherapy is marked by a regenerative burst of new immune cells, and the vaccine would take advantage of this reaction to effect an even stronger immune response to the virus, Mitchell said.

The researchers will publish their findings in the February 2008 print issue of the journal Neuro-Oncology. The study was published early online on October 19, 2007. The research was funded by the National Institutes of Health, The Brain Tumor Society and Accelerate Brain Cancer Cure, a not-for-profit organization that supports research to hasten a cure for brain cancer.

In healthy people with fully functional immune systems, the initial HCMV infection can be symptom-free or it can be associated with mild flulike symptoms. After infection, the virus becomes dormant and stays that way for the life of the infected person. But in people with weakened immune systems -- such as AIDS patients or those undergoing bone marrow transplant -- HCMV can become reactivated and cause more severe illnesses, such as pneumonia.

HCMVs association with brain tumors was first demonstrated in 2002 by researchers at the University of Alabama - Birmingham, but their results had not been repeated despite several attempts.

We not only confirmed the virus association with the tumors but also saw that patients with glioblastoma multiforme had detectable virus in their bloodstreams, where the comparative group did not, Mitchell said. This association may help us assess the success of vaccine treatment, since we will be better able to monitor response in patients, even after their tumors have been removed.

Based on the results of this study, Duke researchers have developed a vaccine that targets HCMV and are conducting a clinical trial to assess the vaccines safety and its effectiveness at building immunity to HCMV in patients with brain tumors. In the trial, which will complete enrollment this year, the vaccine is given monthly to cancer patients in conjunction with chemotherapy for as long as their tumors remain stable.

Were encouraged by the early results were seeing in the clinical trial and were pleased that the initial study enabled us to proceed with testing this vaccine in patients, Mitchell said. Because HCMV is present in such a large number of glioblastoma multiforme patients, the development of an effective treatment that targets the virus could have significant implications for this deadly disease.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Developmental, neurologic problems common in extremely preterm infants
2. Iron supplementation for a common side effect
3. Genetic Breakthrough in Common Eye Problem
4. Common Cold Found to Fight Cancer Cells
5. Side Effects Of Some Common Drugs
6. E. coli strains resistant to a common antibiotic
7. Gastrointestinal ills more common in diabetics
8. Toxic effects common with AIDS treatments
9. Common contraception
10. Drooping eyelids more common in men
11. Unnatural death common in mentally ill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: